Inmed pharmaceuticals demonstrates inm-901 as an oral formulation targeting alzheimer's disease

High bioavailability of inm-901 oral formulation provides similar drug concentration levels in the brain as intraperitoneal (ip) injection vancouver, british columbia--(newsfile corp. - august 20, 2024) - inmed pharmaceuticals inc. (nasdaq: inm) ("inmed" or the "company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today confirms inm-901 as an oral formulation that will be utilized in its development programs for alzheimer's disease. recent preclinical studies have demonstrated that inm-901, a proprietary small molecule drug candidate, can be administered orally and achieve therapeutic levels in the brain comparable to those obtained through intraperitoneal ("ip") injection, which is a common route of administration for preclinical investigation of neurodegenerative diseases.
INM Ratings Summary
INM Quant Ranking